1.
Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors.
Huang, M, Chen, Z, Lang, C, Chen, J, Yang, B, Xue, L, Zhang, Y
Pakistan journal of pharmaceutical sciences. 2018;(6(Special)):2891-2895
Abstract
Present investigation is conducted to investigate the clinical efficacy of mesalazine in combination with the Bifid Triple Viable Capsules on the ulcerative colitis (UC) and the resultant effect on the inflammatory factors (TNF-α, IL-8 and IL-10) of UC patients. A total of 120 UC patients who were admitted to this hospital for treatment between May 2014 and February 2018 were enrolled in this study and divided randomly into the research group and control group, with 60 patients in each group. For patients in the two groups, they underwent medication via mesalazine, while those in the research group additionally received the medication by Bifid Triple Viable Capsules. Following treatment, we evaluated the clinical efficacy, as well as the disease activity index (DAI) of UC, score of clinical symptoms, changes in the inflammatory factors (TNF-α, IL-8 and IL-10) and the adverse reactions to drugs before and after treatment. The total effectiveness rate in the research group was 90.0%, significantly higher than 72.5% in the control group, and the difference had statistical significance (P < 0.05). Before treatment, we assessed the UCDAI and clinical symptoms, and found that there were no statistically significant differences in these indicators between two groups (P>0.05); however, after treatment, both of UCDAI and clinical symptoms scores were decreased evidently in two groups (P<0.05), while the decreases in the research group were more significant (P < 0.05). In addition, following treatment, the levels of TNF-α and IL-8 were all decreased in two groups, with an acute increase in IL-10 (all P<0.01), and the alterations in these indicators in the research group were much more significant than those in the control group (all P <0.05). For adverse reactions, the incidence rate in the research group was 6.67%, significantly lower than 33.33% in the control group (P <0.05). Mesalazine in combination with Bifid Triple Viable Capsules shows a magnificent protective effect on the mucosa of UC patients, and curb the UC-related inflammatory reactions effectively. Thus, it is a safe and reliable method that is worthy of being promoted in clinical practice.
2.
[Effect of shenqi fuzheng injection combined with chemotherapy in treating colorectal cancer].
Zhang, Y, Guo, LL, Zhao, SP
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2010;(3):280-2
Abstract
OBJECTIVE To explore the effect and mechanism of Shenqi Fuzheng Injection (SFI) for assisting of chemotherapy in treating colorectal cancer (CRC). METHODS Forty CRC patients were randomly and equally assigned to two groups, the control group received chemotherapy of FOLFOX protocol and the test group treated with the same chemotherapy combining with SFI. The CD4+ CD25+ regulatory T (Treg) cells, tumor necrosis factor-alpha (TNF-alpha) and interleukin-12 (IL-12) in peripheral blood were determined before and after treatment, and the toxicity of chemotherapy assessed according to the WHO criteria for acute and subacute toxic reaction of anticancer drugs. RESULTS Two cases in the control group were lost during the observing period. The amount of CD4+ CD25+ Treg cells in peripheral blood in CRC patients was significantly higher than the normal range (P<0.05), which was lowered significantly after treatment in both groups (P<0.05). Levels of TNF-alpha and IL-12 significantly elevated in the test group after treatment but lowered in the control group, showing significant difference between groups (both P<0.05). As compared with the control group, the adverse reaction to the chemotherapy was significantly lessened in the test group (P<0.05). CONCLUSION Using SFI for assisting chemotherapy could not only improve the immune function of organism to enhance the effect of chemotherapy, but also reduce the adverse reaction of the chemotherapy.